Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arrowhead Pharmaceuticals, Inc. - Common Stock
(NQ:
ARWR
)
74.95
-0.59 (-0.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
↗
June 28, 2024
Low priced stocks to buy for growth provide great value to investors in the $20 range and are expected to pop before 2025.
Via
InvestorPlace
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
June 25, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Why Arrowhead Pharmaceuticals (ARWR) Stock Is Seeing Blue Skies
↗
June 24, 2024
Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday's session. The company announced that it presented preclinical data on ARO-INHBE.
Via
Benzinga
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
June 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
↗
June 24, 2024
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.
Via
Benzinga
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
↗
June 03, 2024
Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran.
Via
Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
↗
June 03, 2024
Via
Benzinga
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
June 03, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
May 31, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
May 29, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
May 28, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
May 20, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
↗
May 14, 2024
These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet.
Via
InvestorPlace
ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024
↗
May 09, 2024
ARWR stock results show that Arrowhead Pharma missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
May 09, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
May 10, 2024
Via
Benzinga
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
↗
May 02, 2024
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses...
Via
Benzinga
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
May 02, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
April 29, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
April 26, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
April 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
April 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Turnstone Biologics Appoints William Waddill to its Board of Directors
April 16, 2024
From
Turnstone Biologics Corp.
Via
GlobeNewswire
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
April 07, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
↗
April 05, 2024
With risk-on sentiment in place, investors may be looking for the most undervalued Russell 2000 stocks to buy in April.
Via
InvestorPlace
NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling
↗
April 04, 2024
The Nasdaq 100 closed higher by around 0.2% on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 01, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
March 25, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
↗
March 13, 2024
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.
Via
InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
↗
March 11, 2024
The Russell 2000 is up about 4% year to date, and could push higher, taking the most undervalued Russell 2000 stocks along for the ride.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
